A total of 118 patients will be randomised into two study groups: ipilimumab and nivolumab alone or with UV1 vaccination. Treatment will be continued until disease progression, unacceptable toxicity for a maximum of 2 years. Because of the potential for pseudoprogression/tumour immune infiltration, this study will allow patients to remain on study treatment after apparent radiographic progression, provided the risk/benefit ratio is judged to be favourable.
Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
BMC Cancer, 21 (1), 1089
Immunotherapy for malignant pleural mesothelioma
Tidsskr Nor Laegeforen, 141
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study